Monopar Therapeutics Inc. (NASDAQ: MNPR) reported Q3 EPS of ($0.37), $0.27 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Monopar Therapeutics Inc. (MNPR) click here.